Transient Expression of CD20 Antigen (Pan B Cell Marker) in Activated Lymph Node T Cells

Murayama, Yuichi; Mukai, Ryozaburo; Sata, Tetsutaro; Matsunaga, Satoko; Noguchi, Atsushi; Yoshikawa, Yasuhiro

doi:10.1111/j.1348-0421.1996.tb01096.x

Cited by 43 publications

(34 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this could be the result of nonspecific T-cell binding, no increased background staining was observed with the isotype mAb. Notably, CD20 has been identified as an activation marker on T cells in simian immunodeficiency virus (SIV)-infected rhesus monkeys (28). Positive staining was also found after PHA activation of PBMC from the owl monkey (Aotus lemurinus griseimembra; González et al, unpublished data).…”

Section: Resultsmentioning

confidence: 94%

An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotton-top tamarin

et al. 2001

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 94%

An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotton-top tamarin

et al. 2001

View full text Add to dashboard Cite

“…However, it has not been clarified whether normal immature T cells (normal counterpart of T cell ALL blasts) expressing CD20 exist in humans. It was reported that some mature T cells from monkey lymph nodes, not from peripheral blood, gained in cell surface of CD20 after activating with interleukin-2 and concanavalin A [7]. Such activation usually induces blastoid transformation of T cells.…”

Section: Discussionmentioning

confidence: 98%

CD20-positive T cell leukemia/lymphoma: case report and review of the literature

Yokose

Ogata

Sugisaki

et al. 2001

Annals of Hematology

View full text Add to dashboard Cite

We report on a case of CD20-positive peripheral T cell lymphoma. The lymphoma cell was positive for CD20 and T cell lineage markers such as cytoplasmic CD3, CD4, and CD5 and had a monoclonal rearrangement of the T cell receptor (TCR) gamma chain gene. The clinical characteristics resembled angioimmunoblastic lymphadenopathy: spontaneous regression of lymphadenopathy and immunological abnormalities such as polyclonal hypergammaglobulinemia, positive results of direct and indirect antiglobulin tests, and a high antinuclear antibody titer. We reviewed seven cases of CD20-positive T cell malignancies including the present case. Three were immature T cell malignancies (acute lymphoblastic leukemia) and four were peripheral T cell malignancies (non-Hodgkin's lymphoma and chronic lymphocytic leukemia). Hepatomegaly and/or splenomegaly were common features. Further cases must be evaluated to understand the clinical significance of the CD20 expression on the surface of T cell malignancies.

show abstract

“…IFN-a (500-1000 U/ ml, 24-48 h) induces significant upregulation of CD20 on peripheral blood lymphocytes of patients with B-CLL with no significant increase of CD20 on normal lymphocytes . Activation of lymph node T cells by mitogen and IL-2 induces CD20 expression (Murayama et al, 1996). IFN-g (100-1000 U/ ml, 48-72 h) augments CD20 surface expression on human myeloma cells (Treon et al, 2001;Jazirehi et al, 2002).…”

Section: Modulation Of Cd20 Expressionmentioning

confidence: 99%

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

2005

View full text Add to dashboard Cite

The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has significantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular nonHodgkin's lymphoma (NHL). The exact in vivo mechanisms of action of rituximab are not fully understood, although antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis have been suggested. We have proposed that modifications of the cellular signaling pathways by rituximab may be crucial for its clinical response. The B-cell restricted cell surface phosphoprotein CD20 is involved in many cellular signaling events including proliferation, activation, differentiation, and apoptosis upon crosslinking. Monomeric rituximab chemosensitizes drug-resistant NHL cells via selective downregulation of antiapoptotic factors through the type II mitochondrial apoptotic pathway. Several signaling pathways are affected by rituximab which are implicated in the underlying molecular mechanisms of chemosensitization. ARL (acquired immunodeficiency syndrome (AIDS)-related lymphoma) and non-ARL cell lines have been examined as in vitro model systems. In ARL, rituximab diminishes the activity of the p38MAPK signaling pathway resulting in inhibition of the interleukin (IL)-10/IL-10R autocrine/ paracrine cytokine autoregulatory loop leading to the inhibition of constitutive STAT-3 activity and subsequent downregulation of Bcl-2 expression leading to chemosensitization. Rituximab upregulates Raf-1 kinase inhibitor protein (RKIP) expression in non-ARL cells. Through physical association with Raf-1 and nuclear factor jB (NF-jB)-inducing kinase (NIK), RKIP negatively regulates two major survival pathways, namely, the extracellular signal-regulated kinase1/2 (ERK1/2) and the NFjB pathways, respectively. Downmodulation of the ERK1/2 and NF-jB pathways inhibits the transcriptional activity of AP-1 and NF-jB transcription factors, respectively, both of which lead to the downregulation of Bcl-xL (Bcl-2 related gene (long alternatively spliced variant of Bcl-x gene)) transcription and expression and sensitization to drug-induced apoptosis. Bcl-xL -overexpressing cells corroborated the pivotal role of Bcl-xL in chemosensitization. The specificity of rituximab-mediated signaling and functional effects were corroborated by the use of specific pharmacological inhibitors. Many patients do not respond and/or relapse and the mechanisms of unresponsiveness are unknown. Rituximab-resistant B-NHL clones were generated to investigate the acquired resistance to rituximab-mediated signaling, and chemosensitization. Resistant clones display different phenotypic, genetic and functional properties compared to wildtype cells. This review summarizes the data highlighting a novel role of rituximab as a signal-inducing antibody and as a chemosensitizing agent through negative regulation of major survival pathways. Studies presented herein also reveal several intr...

show abstract

Transient Expression of CD20 Antigen (Pan B Cell Marker) in Activated Lymph Node T Cells

Cited by 43 publications

References 19 publications

An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotton-top tamarin

An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotton-top tamarin

CD20-positive T cell leukemia/lymphoma: case report and review of the literature

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

Contact Info

Product

Resources

About